BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30765268)

  • 1. Association of multidimensional comorbidities with survival, toxicity, and unplanned hospitalizations in older adults with metastatic colorectal cancer treated with chemotherapy.
    Kim KH; Lee JJ; Kim J; Zhou JM; Gomes F; Sehovic M; Extermann M
    J Geriatr Oncol; 2019 Sep; 10(5):733-741. PubMed ID: 30765268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using heat maps to assess the multidimensional association of comorbidities with survival in older cancer patients treated with chemotherapy.
    Lee JJ; Kim J; Sehovic M; Chen L; Extermann M
    J Geriatr Oncol; 2017 Sep; 8(5):336-342. PubMed ID: 28739160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer.
    Firat S; Bousamra M; Gore E; Byhardt RW
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):1047-57. PubMed ID: 11958901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer.
    Singh N; Singh PS; Aggarwal AN; Behera D
    Clin Lung Cancer; 2016 May; 17(3):205-213.e1. PubMed ID: 26589440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study.
    Lund CM; Vistisen KK; Dehlendorff C; Rønholt F; Johansen JS; Nielsen DL
    Acta Oncol; 2018 Nov; 57(11):1445-1454. PubMed ID: 30375911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer.
    Wildes TM; Ruwe AP; Fournier C; Gao F; Carson KR; Piccirillo JF; Tan B; Colditz GA
    J Geriatr Oncol; 2013 Jul; 4(3):227-34. PubMed ID: 23795224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
    Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center.
    Sharma V; Sharma A; Raina V; Dabkara D; Mohanti BK; Shukla NK; Pathy S; Thulkar S; Deo SVS; Kumar S; Sahoo RK
    BMC Cancer; 2021 May; 21(1):630. PubMed ID: 34049505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study.
    Benderra MA; Serrano AG; Paillaud E; Tapia CM; Cudennec T; Chouaïd C; Lorisson E; de la Taille A; Laurent M; Brain E; Bringuier M; Gligorov J; Caillet P; Canoui-Poitrïne F
    ESMO Open; 2023 Oct; 8(5):101831. PubMed ID: 37832389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
    Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
    J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials.
    Abdel-Rahman O
    Clin Colorectal Cancer; 2019 Mar; 18(1):e61-e68. PubMed ID: 30348618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.
    Price TJ; Zannino D; Wilson K; Simes RJ; Cassidy J; Van Hazel GA; Robinson BA; Broad A; Ganju V; Ackland SP; Tebbutt NC
    Ann Oncol; 2012 Jun; 23(6):1531-6. PubMed ID: 22039086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
    Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for brain metastases in patients with metastatic colorectal cancer.
    Christensen TD; Palshof JA; Larsen FO; Høgdall E; Poulsen TS; Pfeiffer P; Jensen BV; Yilmaz MK; Christensen IJ; Nielsen D
    Acta Oncol; 2017 May; 56(5):639-645. PubMed ID: 28447565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.
    Mlecnik B; Van den Eynde M; Bindea G; Church SE; Vasaturo A; Fredriksen T; Lafontaine L; Haicheur N; Marliot F; Debetancourt D; Pairet G; Jouret-Mourin A; Gigot JF; Hubert C; Danse E; Dragean C; Carrasco J; Humblet Y; Valge-Archer V; Berger A; Pagès F; Machiels JP; Galon J
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases.
    Yamashita S; Odisio BC; Huang SY; Kopetz SE; Ahrar K; Chun YS; Conrad C; Aloia TA; Gupta S; Harmoush S; Hicks ME; Vauthey JN
    Eur J Surg Oncol; 2017 Jun; 43(6):1040-1049. PubMed ID: 28187878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
    Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
    Vijayvergia N; Li T; Wong YN; Hall MJ; Cohen SJ; Dotan E
    Cancer; 2016 Oct; 122(20):3191-3198. PubMed ID: 27379436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.